Kurotaki H, Tsushima Y, Nagai K, Yagihashi S
Department of Pathology, Hirosaki University School of Medicine, Hirosaki, Japan.
Acta Haematol. 2000;102(3):115-23. doi: 10.1159/000040984.
Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS). To explore the role of apoptosis in hematological disorders, we examined the frequency of apoptotic cells by the in situ end labeling method in bone marrow specimens from 37 patients with MDS [refractory anemia (RA) 10 cases, RA with excess of blasts (RAEB) 27 cases including 12 cases with leukemic transformation], 12 patients with MDS-derived acute myelogenous leukemia (AML) and 13 patients with de novo AML. In addition, we investigated the relationship of apoptosis to the immunohistochemical expression of bcl-2 and p53 in these cases, and the association of apoptosis, bcl-2, and p53 with the leukemic evolution of MDS by examining sequential bone marrow samples of the same patient from the time of initial diagnosis to the time of overt leukemia. The percentage frequency of apoptotic cells was significantly greater in MDS (RA: 9.46 +/- 2.99%, m +/- SD; RAEB: 5. 60 +/- 3.09) as compared with those in MDS-derived AML (0.62 +/- 0. 37), de novo AML (0.28 +/- 0.11) and controls (1.00 +/- 0.59). On the other hand, the cases of RAEB with leukemic transformation exhibited a lower frequency of apoptotic cells and a higher frequency of bcl-2- and p53-positive cells than those without transformation. When the RAEB cases transformed to AML, the frequency of apoptotic cells was significantly reduced (2.96 +/- 1. 54 --> 0.62 +/- 0.37), while the frequencies of bcl-2-positive cells and p53-positive cells were greater (10.88 +/- 3.66 --> 30.54 +/- 7. 14, and 20.21 +/- 6.21 --> 32.34 +/- 14.71, respectively). In contrast to MDS-derived AML, over a half of de novo AML cases showed few p53-positive cells. These findings corroborate the earlier notion that apoptosis may play a substantial role in dysplastic and ineffective hematopoiesis in MDS. It is also suggested that the suppression of apoptosis associated with enhanced bcl-2 expression and p53 accumulation increases the probability of developing leukemia in MDS, and that oncogenetic development might be different between MDS-derived AML and de novo AML.
细胞凋亡及其调节异常与骨髓增生异常综合征(MDS)中发育异常和无效造血以及骨髓的肿瘤转化有关。为了探讨细胞凋亡在血液系统疾病中的作用,我们采用原位末端标记法检测了37例MDS患者[难治性贫血(RA)10例,伴有原始细胞增多的RA(RAEB)27例,其中12例发生白血病转化]、12例MDS衍生的急性髓性白血病(AML)患者和13例原发性AML患者骨髓标本中凋亡细胞的频率。此外,我们研究了这些病例中细胞凋亡与bcl-2和p53免疫组化表达的关系,以及通过检查同一患者从初诊到明显白血病时期的连续骨髓样本,探讨细胞凋亡、bcl-2和p53与MDS白血病演变的关联。与MDS衍生的AML(0.62±0.37)、原发性AML(0.28±0.11)和对照组(1.00±0.59)相比,MDS(RA:9.46±2.99%,平均值±标准差;RAEB:5.60±3.09)中凋亡细胞的百分比频率显著更高。另一方面,发生白血病转化的RAEB病例与未转化病例相比,凋亡细胞频率较低,bcl-2和p53阳性细胞频率较高。当RAEB病例转化为AML时,凋亡细胞频率显著降低(2.96±1.54→0.62±0.37),而bcl-2阳性细胞和p53阳性细胞频率增加(分别为10.88±3.66→30.54±7.14和20.21±6.21→32.34±14.71)。与MDS衍生的AML相反,超过一半的原发性AML病例显示p53阳性细胞很少。这些发现证实了早期的观点,即细胞凋亡可能在MDS的发育异常和无效造血中起重要作用。还提示与bcl-2表达增强和p53积累相关的细胞凋亡抑制增加了MDS发生白血病的可能性,并且MDS衍生的AML和原发性AML之间的肿瘤发生发展可能不同。